Merck Seeks Stop Of Royalty Payments For Diabetes Patents

By Jacob Batchelor (August 31, 2015, 4:40 PM EDT) -- Merck Sharp & Dohme Corp. on Friday asked a Delaware federal judge to either invalidate or find it no longer needs to pay royalties on 10 patents related to its Januvia and Janumet treatments for Type II diabetes, arguing the patents were either invalid or not specific enough to warrant continued payments....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!